Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily affecting men 20–60 years of age. To date, no consensus has been reached regarding the classification of CSC, and a wide variety of interventions have been proposed, reflecting the controversy associated with treating this disease. The recent publication of appropriately powered randomised controlled trials such as the PLACE trial, as well as large retrospective, non-randomised treatment studies regarding the treatment of CSC suggest the feasibility of a more evidence-based approach when considering treatment options. The aim of this review is to provide a comprehensive overview of the current rationale and evidence with respect to the variety of interventions available for treating CSC, including pharmacology, laser treatment, and photodynamic therapy. In addition, we describe the complexity of CSC, the challenges associated with treating CSC, and currently ongoing studies. Many treatment strategies such as photodynamic therapy using verteporfin, oral mineralocorticoid antagonists, and micropulse laser treatment have been reported as being effective. Currently, however, the available evidence suggests that half-dose (or half-fluence) photodynamic therapy should be the treatment of choice in chronic CSC, whereas observation may be the preferred approach in acute CSC. Nevertheless, exceptions can be considered based upon patient-specific characteristics.

中心性浆液性脉络膜视网膜病变 (CSC) 是中心视力丧失的常见原因，主要影响 20-60 岁的男性。迄今为止，尚未就 CSC 的分类达成共识，并提出了多种干预措施，反映了与治疗该疾病相关的争议。最近发表的具有适当功效的随机对照试验（如 PLACE 试验）以及关于 CSC 治疗的大型回顾性非随机治疗研究表明，在考虑治疗方案时采用更加循证的方法是可行的。本综述的目的是全面概述当前可用于治疗 CSC 的各种干预措施的基本原理和证据，包括药理学、激光治疗和光动力疗法。此外，我们描述了 CSC 的复杂性、与治疗 CSC 相关的挑战以及目前正在进行的研究。据报道，许多治疗策略（例如使用维替泊芬的光动力疗法、口服盐皮质激素拮抗剂和微脉冲激光治疗）是有效的。然而，目前可用的证据表明，半剂量（或半能量）光动力疗法应该是慢性 CSC 的治疗选择，而观察可能是急性 CSC 的首选方法。然而，可以根据患者的具体特征考虑例外情况。据报道，微脉冲激光治疗是有效的。然而，目前可用的证据表明，半剂量（或半能量）光动力疗法应该是慢性 CSC 的治疗选择，而观察可能是急性 CSC 的首选方法。然而，可以根据患者的具体特征考虑例外情况。据报道，微脉冲激光治疗是有效的。然而，目前可用的证据表明，半剂量（或半能量）光动力疗法应该是慢性 CSC 的治疗选择，而观察可能是急性 CSC 的首选方法。然而，可以根据患者的具体特征考虑例外情况。